why does nobody talk about BPC-157
why does nobody talk about BPC-157. If this has been answered properly somewhere, link me and I will delete.
The three questions, kept separate, because this board runs them together constantly.
Identity: is this the sequence I ordered? Answered by mass spectrometry against a theoretical mass. Quantity: how much peptide is in the vial? Answered by net peptide content, not by area percent. Stability: what happens to it in solution over time? Answered by a stability statement with conditions attached, and almost never asked for.
A certificate that answers one of the three is common. One that answers all three is rare and worth choosing a supplier over. Nothing here is approved for human use in any case, so all three are questions about material rather than about anything else.
Bought small, tested identity first, and only then thought about anything else. That order felt right.
Why identity, not purity, is the test to buy here.
This is a short peptide with a published sequence. Synthesis is not difficult, which means the market is wide and the analytical question shifts. A high area-percent figure tells you the sample is homogeneous; it does not tell you the homogeneous material is the sequence you ordered.
Mass spectrometry, with the theoretical mass alongside the measured one, converts a purity claim into an identity claim. It costs a little more and it answers the question that actually matters. Ask for it, and ask suppliers whether they can provide it before you order — the answers are informative in themselves.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.
Left up. It distinguishes rodent work from human work, which is the standard on this board.
Kept a reconstituted vial too long out of curiosity and learned something about solution stability I would rather have read.
Regulatory classification differs between jurisdictions and has changed in several of them recently. Any answer to a status question needs a place and a date attached.
identity, quantity, stability — three separate questions
Assumed regulatory status was static and it was not. Checked again this year and the answer had changed where I live.
Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.
Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.
a fifteen-residue peptide is easy to make and easy to make badly
Yes — the rodent literature is real and it is rodent literature. The gap to a human claim is enormous and it gets crossed in one sentence here.
regulatory status varies by jurisdiction and it has moved recently
Not convinced. A high purity figure with no identity confirmation tells you the sample is homogeneous, not that it is what you ordered.
Correcting myself: I said the regulatory position had not changed and in that jurisdiction it has.
- 1Regulatory classification differs between jurisdictions and has changed in…7 comments in this branch · started by u/bpc_sceptic